Summary of the best evidence for anticoagulation and bleeding risk management in patients with extracorporeal membrane oxygenation.
10.3760/cma.j.cn121430-20221018-00926
- Author:
Xiaojing GUO
1
;
Yubiao GAI
;
Wei WANG
;
Yuchen ZHANG
;
Huiting SUN
Author Information
1. Department of Intensive Care Unit, Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong, China. Corresponding author: Gai Yubiao, Email: gaiyubiao@126.com.
- Publication Type:Journal Article
- MeSH:
Humans;
Extracorporeal Membrane Oxygenation/adverse effects*;
Blood Coagulation;
Hemorrhage/etiology*;
Anticoagulants/adverse effects*;
Thrombosis/prevention & control*;
Retrospective Studies
- From:
Chinese Critical Care Medicine
2023;35(9):963-967
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate and summarize the relevant evidence of anticoagulation and bleeding risk management in patients with extracorporeal membrane oxygenation (ECMO), and provide the evidence-based basis for the management of anticoagulation and bleeding during ECMO treatment.
METHODS:According to the evidence "6S" pyramid model, all evidence on ECMO anticoagulation management and bleeding risk was searched in relevant databases, organizations and guideline websites at home and abroad. Evidence types included guidelines, expert consensus, systematic evaluation, Meta-analysis and original study. The search time limit was from May 31, 2012 to May 31, 2022. Two researchers with evidence-based research background conducted independent literature quality evaluation of the retrieved evidence, and the evidence that met the quality standards was extracted and summarized based on the opinions of industry experts.
RESULTS:A total of 315 articles were retrieved, and 13 articles were included, including 3 guidelines, 6 expert consensus, and 4 Meta-analysis. A total of 27 best evidences were summarized from 7 aspects, including the selection of ECMO anticoagulation, anticoagulation in priming, anticoagulation in operation, anticoagulation monitoring, bleeding and treatment, thrombosis and treatment, and prevention and management of terminal limb ischemia.
CONCLUSIONS:This study provides evidence-based basis for bleeding prevention and anticoagulant management in ECMO patients. It is recommended to selectively apply the best evidence after evaluating the clinical environmental conditions of medical institutions, so as to improve the prognosis of ECMO patients.
